Pharmafile Logo

Measures for measures

March 15, 2019 |  

Why pharma’s marketing metrics must close the loop

- PMLiVE

The March issue of PME tackles the complexities of choosing the right digital marketing KPIs.

Assessing marketing effectiveness in the digital world has fast become one of the biggest challenges facing the pharmaceutical industry. Distilling the vast amount of data available to marketeers often results in a dizzying array of KPIs, leaving many with information overload.

Dennis O’Brien, Lucid CEO, believes that the traditional method, in which digital strategy feeds into digital KPIs, needs reversing. “It’s the wrong way round. Digital KPIs should instead be driven by – and feed into – the marketing strategy.” Digital tools provide an amazing opportunity to reach, connect and understand customers in a way that was not previously possible. This enables one to ‘close the loop’, understand what isn’t working, and then ask, how can we fix it?

Nigel Horn, Managing Director of digital and creative design company Bluedog, a Lucid Group company, also believes that the key is to start and end with the marketing objectives: it’s a circular journey. “The closed-loop approach allows us to measure not only whether we’re touching our target customers, but also, crucially, whether we’re influencing them in the ways we need to change behaviour.” comments Nigel. Bluedog capture this principle perfectly in The Dog TestTM, whereby tactics and metrics are evaluated to see if they meet marketing and brand objectives.

To find out more, read the full article here https://bit.ly/2O6XNBJ

This content was provided by Lucid Group Communications Limited

Company Details

 Latest Content from  Lucid Group Communications Limited 

Lucid celebrate big wins at PMEA 2015

Success for Lucid at PMEA 2015

Lucid invests in their Futures programme with a new hire

Lucid Group continues their expansion

Janus kinase inhibitors are amongst the most read abstracts at the American College of Rheumatology 2015

Rheumatologists eagerly await trial data for Janus kinase inhibitors

Making a difference to patients with IBD

Changing lives with medical education

Lucid Group showcases new KOL identification and mapping tool

Advancing Expert identification with digital new tool from Lucid Group

Lucid CEO discusses his inspiration and passion for changing patients’ lives

Changing patients' lives with innovative methodologies in medical education

Lucid Group starts new trend for CME in IBD education

A tailored educational event in IBD